期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 66, 期 4, 页码 912-919出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkq528
关键词
cyclic lipopeptide; Gram-positive infections; registry
资金
- Novartis Pharma AG
- Cubist Pharmaceuticals
- Pfizer
- Merck
- Novartis
Objectives: To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes. Patients and methods: Data from the European Cubicin Outcomes Registry and Experience (EU-CORE (TM)), retrospectively collected at 118 institutions between January 2006 and August 2008, were analysed. Results: Daptomycin treatment was documented in 1127 patients with diverse infections, including complicated skin and soft tissue infections (33%), bacteraemia (22%), endocarditis (12%) and osteomyelitis (6%). It was used empirically, before microbiological results became available, in 53% of patients. Staphylococcus aureus was the most common pathogen (34%), with 52% of isolates resistant to methicillin; coagulase-negative staphylococci and enterococci were also frequent, with 22% of Enterococcus faecium isolates resistant to vancomycin. Daptomycin was used as first-line therapy in 302 (27%) patients. When used second line, the most common reasons for discontinuation of previous antibiotic were treatment failure and toxicity or intolerance. The use of concomitant antibiotics was reported in 65% of patients. Most frequent doses were 6 mg/kg (47%) and 4 mg/kg (32%). The median duration of daptomycin therapy was 10 days (range 1-246 days) in the inpatient setting and 13 days (range 2-189 days) in the outpatient setting. The overall clinical success rate was 79%, with a clinical failure rate of < 10% for all infection types. Low failure rates were observed in first- and second-line therapy (6% and 8%, respectively). Daptomycin demonstrated a favourable safety and tolerability profile regardless of treatment duration. Conclusions: Daptomycin has a relevant role in the treatment of Gram-positive infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据